Lire le communiqu\u00e9 de presse<\/a><\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":"
Pierre Fabre M\u00e9dicament, deuxi\u00e8me laboratoire pharmaceutique priv\u00e9 fran\u00e7ais, et Grupo Biotoscana SL (GBT), importante soci\u00e9t\u00e9 pharmaceutique sp\u00e9cialis\u00e9e d\u2019Am\u00e9rique Latine, ont sign\u00e9 aujourd\u2019hui un accord de commercialisation dans le domaine de l\u2019oncologie. Selon les termes de cet accord, GBT commercialisera Navelbine\u00ae (Vinorelbine) sous ses formes injectable et orale, Javlor\u00ae (Vinflunine) et Busilvex\u00ae (Busulfan) en Colombie, au Chili, en \u00c9quateur et au P\u00e9rou.<\/p>\n","protected":false},"author":1,"featured_media":8357,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,13],"tags":[],"class_list":["post-16048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-nos-adherents"],"yoast_head":"\n
Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l'oncologie - MabDesign<\/title>\n<meta name=\"description\" content=\"Pierre Fabre M\u00e9dicament, deuxi\u00e8me laboratoire pharmaceutique priv\u00e9 fran\u00e7ais, et Grupo Biotoscana SL (GBT), importante soci\u00e9t\u00e9 pharmaceutique sp\u00e9cialis\u00e9e d\u2019Am\u00e9rique Latine, ont sign\u00e9 aujourd\u2019hui un accord de commercialisation dans le domaine de l\u2019oncologie. Selon les termes de cet accord, GBT commercialisera Navelbine\u00ae (Vinorelbine) sous ses formes injectable et orale, Javlor\u00ae (Vinflunine) et Busilvex\u00ae (Busulfan) en Colombie, au Chili, en \u00c9quateur et au P\u00e9rou.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l'oncologie - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Pierre Fabre M\u00e9dicament, deuxi\u00e8me laboratoire pharmaceutique priv\u00e9 fran\u00e7ais, et Grupo Biotoscana SL (GBT), importante soci\u00e9t\u00e9 pharmaceutique sp\u00e9cialis\u00e9e d\u2019Am\u00e9rique Latine, ont sign\u00e9 aujourd\u2019hui un accord de commercialisation dans le domaine de l\u2019oncologie. Selon les termes de cet accord, GBT commercialisera Navelbine\u00ae (Vinorelbine) sous ses formes injectable et orale, Javlor\u00ae (Vinflunine) et Busilvex\u00ae (Busulfan) en Colombie, au Chili, en \u00c9quateur et au P\u00e9rou.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-25T14:32:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"215\" \/>\n\t<meta property=\"og:image:height\" content=\"210\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l’oncologie\",\"datePublished\":\"2016-07-25T14:32:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/\"},\"wordCount\":109,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg\",\"articleSection\":[\"Actualit\u00e9s\",\"Nos adh\u00e9rents\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/\",\"name\":\"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l'oncologie - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg\",\"datePublished\":\"2016-07-25T14:32:05+00:00\",\"description\":\"Pierre Fabre M\u00e9dicament, deuxi\u00e8me laboratoire pharmaceutique priv\u00e9 fran\u00e7ais, et Grupo Biotoscana SL (GBT), importante soci\u00e9t\u00e9 pharmaceutique sp\u00e9cialis\u00e9e d\u2019Am\u00e9rique Latine, ont sign\u00e9 aujourd\u2019hui un accord de commercialisation dans le domaine de l\u2019oncologie. Selon les termes de cet accord, GBT commercialisera Navelbine\u00ae (Vinorelbine) sous ses formes injectable et orale, Javlor\u00ae (Vinflunine) et Busilvex\u00ae (Busulfan) en Colombie, au Chili, en \u00c9quateur et au P\u00e9rou.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg\",\"width\":215,\"height\":210},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l’oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l'oncologie - MabDesign","description":"Pierre Fabre M\u00e9dicament, deuxi\u00e8me laboratoire pharmaceutique priv\u00e9 fran\u00e7ais, et Grupo Biotoscana SL (GBT), importante soci\u00e9t\u00e9 pharmaceutique sp\u00e9cialis\u00e9e d\u2019Am\u00e9rique Latine, ont sign\u00e9 aujourd\u2019hui un accord de commercialisation dans le domaine de l\u2019oncologie. Selon les termes de cet accord, GBT commercialisera Navelbine\u00ae (Vinorelbine) sous ses formes injectable et orale, Javlor\u00ae (Vinflunine) et Busilvex\u00ae (Busulfan) en Colombie, au Chili, en \u00c9quateur et au P\u00e9rou.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/","og_locale":"en_US","og_type":"article","og_title":"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l'oncologie - MabDesign","og_description":"Pierre Fabre M\u00e9dicament, deuxi\u00e8me laboratoire pharmaceutique priv\u00e9 fran\u00e7ais, et Grupo Biotoscana SL (GBT), importante soci\u00e9t\u00e9 pharmaceutique sp\u00e9cialis\u00e9e d\u2019Am\u00e9rique Latine, ont sign\u00e9 aujourd\u2019hui un accord de commercialisation dans le domaine de l\u2019oncologie. Selon les termes de cet accord, GBT commercialisera Navelbine\u00ae (Vinorelbine) sous ses formes injectable et orale, Javlor\u00ae (Vinflunine) et Busilvex\u00ae (Busulfan) en Colombie, au Chili, en \u00c9quateur et au P\u00e9rou.","og_url":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/","og_site_name":"MabDesign","article_published_time":"2016-07-25T14:32:05+00:00","og_image":[{"width":215,"height":210,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg","type":"image\/jpeg"}],"author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l’oncologie","datePublished":"2016-07-25T14:32:05+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/"},"wordCount":109,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg","articleSection":["Actualit\u00e9s","Nos adh\u00e9rents"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/","url":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/","name":"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l'oncologie - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg","datePublished":"2016-07-25T14:32:05+00:00","description":"Pierre Fabre M\u00e9dicament, deuxi\u00e8me laboratoire pharmaceutique priv\u00e9 fran\u00e7ais, et Grupo Biotoscana SL (GBT), importante soci\u00e9t\u00e9 pharmaceutique sp\u00e9cialis\u00e9e d\u2019Am\u00e9rique Latine, ont sign\u00e9 aujourd\u2019hui un accord de commercialisation dans le domaine de l\u2019oncologie. Selon les termes de cet accord, GBT commercialisera Navelbine\u00ae (Vinorelbine) sous ses formes injectable et orale, Javlor\u00ae (Vinflunine) et Busilvex\u00ae (Busulfan) en Colombie, au Chili, en \u00c9quateur et au P\u00e9rou.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/PF-Biotoscana-CP201607-1.jpg","width":215,"height":210},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-medicament-et-grupo-biotoscana-signent-un-accord-de-commercialisation-dans-le-domaine-de-loncologie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Pierre Fabre M\u00e9dicament et Grupo Biotoscana signent un accord de commercialisation dans le domaine de l’oncologie"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=16048"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16048\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/8357"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=16048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=16048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=16048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}